Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here, using the novel BiXAb™ tetravalent format platform, we generated bispecific antibodies against EGFR, HER2, or HER3 by considering rational epitope combinations. We then screened these bispecific antibodies and compared them with the parental single antibodies and antibody pair combinations. The screen readouts included measuring binding to the cognate receptors (mono and bispecificity), intracellular phosphorylation signaling, cell proliferation, apoptosis and receptor expression, and also immune system engagement assays (antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity). Among the 30 BiXAbs™ tested, we selected 3Patri-1Cetu-Fc, 3Patri-1Matu-Fc and 3Patri-2Trastu-Fc as lead candidates. The in vivo testing of these three highly efficient bispecific antibodies against EGFR and HER2 or HER3 in pre-clinical mouse models of pancreatic cancer showed deep antibody penetration in these dense tumors and robust tumor growth reduction. Application of such semi-rational/semi-empirical approach, which includes various immunological assays to compare pre-selected antibodies and their combinations with bispecific antibodies, represents the first attempt to identify potent bispecific antibodies against ErbB family members in pancreatic cancer.

[1]  J. Mayordomo,et al.  Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. , 2022, The Lancet. Oncology.

[2]  N. Xu,et al.  KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. , 2022, European journal of cancer.

[3]  G. A. Lazar,et al.  Avidity in antibody effector functions and biotherapeutic drug design , 2022, Nature Reviews Drug Discovery.

[4]  Monilola A. Olayioye,et al.  Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancer. , 2022, Molecular cancer therapeutics.

[5]  M. Ladanyi,et al.  Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements , 2022, Cancer discovery.

[6]  L. J. Cook,et al.  The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein , 2022, Pharmacological Reviews.

[7]  H. Yao,et al.  First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study. , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  L. Gros,et al.  Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures , 2021, Cancers.

[9]  J. Colinge,et al.  An R package for generic modular response analysis and its application to estrogen and retinoic acid receptor crosstalk , 2021, Scientific Reports.

[10]  T. Salame,et al.  Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models , 2021, EMBO molecular medicine.

[11]  Monilola A. Olayioye,et al.  A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3 , 2021, mAbs.

[12]  P. Colombo,et al.  Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models , 2021, mAbs.

[13]  A. van Elsas,et al.  Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy , 2020, Journal of Cancer Research and Clinical Oncology.

[14]  Y. Yarden,et al.  Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor , 2020, Cancers.

[15]  L. Shen,et al.  Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. , 2020, Journal of pharmaceutical sciences.

[16]  R. Kontermann,et al.  Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3 , 2020, Molecular Cancer Therapeutics.

[17]  P. Parren,et al.  Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.

[18]  Zhixiang Wang,et al.  Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer , 2018, Cancers.

[19]  B. Geiger,et al.  Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells. , 2019, Cancer research.

[20]  Alexander L. Vahrmeijer,et al.  Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent , 2018, Annals of Surgical Oncology.

[21]  T. Salame,et al.  A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways , 2018, Clinical Cancer Research.

[22]  J. Ajani,et al.  Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. , 2018 .

[23]  M. Gordon,et al.  Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer. , 2018 .

[24]  Tapesh Santra,et al.  Reconstructing static and dynamic models of signaling pathways using Modular Response Analysis , 2018, Current Opinion in Systems Biology.

[25]  P. Gros,et al.  Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade. , 2018, Cancer cell.

[26]  M. Hidalgo,et al.  Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer , 2018, Clinical Cancer Research.

[27]  V. Bachanova,et al.  Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies , 2018, Toxins.

[28]  R. Collins,et al.  Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study , 2017 .

[29]  T. Salame,et al.  An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors , 2017, EMBO molecular medicine.

[30]  K. Hutchinson,et al.  An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression , 2017, Journal of the National Cancer Institute.

[31]  Chengbin Wu,et al.  Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets , 2017, mAbs.

[32]  J. Barret,et al.  Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3 , 2017, Molecular Cancer Therapeutics.

[33]  Jinke Cheng,et al.  Structural basis of a novel heterodimeric Fc for bispecific antibody production , 2017, Oncotarget.

[34]  E. D. de Vries,et al.  ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells , 2017, Oncotarget.

[35]  Chunning Yang,et al.  Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence , 2017, Scientific Reports.

[36]  V. Grantcharova,et al.  Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121) , 2017, npj Systems Biology and Applications.

[37]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[38]  V. Zoete,et al.  Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies , 2016, The Journal of Immunology.

[39]  V. Wroblewski,et al.  A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets* , 2016, The Journal of Biological Chemistry.

[40]  A. Bardelli,et al.  MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations , 2016, Science Translational Medicine.

[41]  M. Chiu,et al.  Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody , 2016, mAbs.

[42]  I. Weissman,et al.  Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential , 2015, PloS one.

[43]  M. Chiu,et al.  Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody* , 2015, The Journal of Biological Chemistry.

[44]  Y. Yarden,et al.  Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer , 2015, Science Signaling.

[45]  D. Weilguny,et al.  Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity , 2015, Clinical Cancer Research.

[46]  Herren Wu,et al.  Insights into the molecular basis of a bispecific antibody's target selectivity , 2015, mAbs.

[47]  M. Ychou,et al.  Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial , 2015, Oncotarget.

[48]  T. T. Poulsen,et al.  Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance , 2015, Molecular Cancer Therapeutics.

[49]  Y. Yarden,et al.  Examination of HER3 targeting in cancer using monoclonal antibodies , 2015, Proceedings of the National Academy of Sciences.

[50]  R. Salgia,et al.  Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy , 2014, Molecular Cancer.

[51]  R. Salgia,et al.  Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy , 2014, Molecular Cancer.

[52]  R. Salgia,et al.  AXL mediates resistance to cetuximab therapy. , 2014, Cancer research.

[53]  N. Blüthgen,et al.  Consequences of feedback in signal transduction for targeted therapies. , 2014, Biochemical Society transactions.

[54]  P. Colombo,et al.  HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models , 2014, Oncotarget.

[55]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[56]  T. Ghayur,et al.  Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig™) Proteins with Unique Activities , 2014, PloS one.

[57]  B. Schoeberl,et al.  MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors , 2013, Molecular Cancer Therapeutics.

[58]  Xiaoping Yang,et al.  Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer , 2013, Breast Cancer Research.

[59]  Y. Yarden,et al.  Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 , 2013, Proceedings of the National Academy of Sciences.

[60]  Daniel C Kirouac,et al.  Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.

[61]  Bertram Klinger,et al.  Supplementary Materials for : Network quantification of EGFR signaling unveils potential for targeted combination therapy , 2022 .

[62]  H. Vié,et al.  The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential , 2013, mAbs.

[63]  Y. Yarden,et al.  Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR , 2013, Proceedings of the National Academy of Sciences.

[64]  Gur Pines,et al.  The ERBB network: at last, cancer therapy meets systems biology , 2012, Nature Reviews Cancer.

[65]  C. Bascoul-Mollevi,et al.  In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. , 2012, Neoplasia.

[66]  Ulrik B. Nielsen,et al.  Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.

[67]  M. Sliwkowski,et al.  A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.

[68]  J. Settleman,et al.  Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. , 2011, Cancer cell.

[69]  Nils Blüthgen,et al.  Strong negative feedback from Erk to Raf confers robustness to MAPK signalling , 2011, Molecular systems biology.

[70]  C. Bascoul-Mollevi,et al.  Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers , 2011, The Journal of Biological Chemistry.

[71]  Jamie B. Spangler,et al.  Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling , 2010, Proceedings of the National Academy of Sciences.

[72]  C. Pyke,et al.  Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. , 2010, Cancer research.

[73]  Werner Scheuer,et al.  Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. , 2009, Cancer research.

[74]  Y. Yarden,et al.  Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis , 2009, Proceedings of the National Academy of Sciences.

[75]  M. Ychou,et al.  Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  D. Lauffenburger,et al.  Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data , 2009, Molecular systems biology.

[77]  G. Adams,et al.  Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro , 2008, British Journal of Cancer.

[78]  P. Parren,et al.  Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. , 2008, Cancer research.

[79]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Sahana Bose,et al.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.

[81]  B. Robert,et al.  In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas , 2007, Clinical Cancer Research.

[82]  M. Nakamoto,et al.  Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines , 2007, Clinical Cancer Research.

[83]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[84]  Y. Yarden,et al.  Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[85]  M. Hung,et al.  The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells , 2004, Cancer Research.

[86]  J. Uhr,et al.  Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  E. Gilles,et al.  Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors , 2002, Nature Biotechnology.

[88]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[89]  P. P. Di Fiore,et al.  Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. , 1992, Cancer research.

[90]  Yang Yang,et al.  Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. , 2015, Cancer research.

[91]  F. Penault-Llorca,et al.  Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.